Switching to long-acting injectable risperidone: Beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia

Autor: R. Teijeiro, Alice Lex, P. Glue, T. De Marinis, Saleem Pt, M.A. Latif, W.J. Arnoldussen

Publikováno v: European Psychiatry. 22:S159

Objective:This subanalysis of the Switch to Risperidone Microspheres (StoRMi) clinical trial, an international, 6-month, open-label investigation of long-term efficacy and safety of risperidone long-acting injectable (RLAI), focuses on a subset of no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f90af5013553b03b35af29e375fa2dba
https://doi.org/10.1016/j.eurpsy.2007.01.516

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.

Autor: Hawley C; Hertfordshire Partnership Foundation Trust, Queen Elizabeth Hospital, Howlands, Welwyn Garden City, Hertfordshire, UK. C.1.Hawley@herts.ac.uk, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K

Publikováno v: Human psychopharmacology [Hum Psychopharmacol] 2010 Jan; Vol. 25 (1), pp. 37-46.

Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.

Autor: Mortimer AM; University of Hull, Hull, UK. A.M.Mortimer@hull.ac.uk, Joyce E, Balasubramaniam K, Choudhary PC, Saleem PT

Publikováno v: Human psychopharmacology [Hum Psychopharmacol] 2007 Oct; Vol. 22 (7), pp. 445-54.